BACKGROUND: Population-based epidemiological studies have shown a convincing association between increased gamma-glutamyltransferase (GGT) activity and components of the metabolic syndrome, type 2 diabetes, hypertension, ischaemic stroke and myocardial infarction. However, little information is available on the interaction between GGT activity and traditional or emerging markers of cardiovascular risk. METHODS: We performed a retrospective analysis to retrieve results of serum GGT, fasting plasma glucose (FPG), creatinine, LDL-cholesterol, HDL-cholesterol, triglycerides and lipoprotein(a) tests performed on outpatients referred by the general practitioners to our laboratory for routine blood testing during the last 5 years. RESULTS: The concentrations of most lipid parameters varied with increasing GGT activities. There were graded, positive, associations of GGT concentrations with LDL-cholesterol, triglycerides, atherogenic index of plasma (AIP) and the total to HDL-cholesterol ratio, whereas a negative association was observed with HDL-cholesterol. Lipoprotein(a) concentrations increased in parallel with GGT activity, though such trend did not reach statistical significance. The frequencies of subjects with undesirable values according to the NCEP-ATP III and AHA/ACC thresholds increased across the spectrum of GGT thresholds for all lipids parameters but lipoprotein(a). These associations remained statistically significant even after adjustment for gender, age, FPG and creatinine concentrations. In multiple linear regression analyses GGT activity predicted plasma concentrations of LDL-cholesterol, triglycerides, HDL-cholesterol (negatively), AIP and the total to HDL-cholesterol ratio independently of age, gender, impaired fasting glucose/diabetes and creatinine levels. CONCLUSIONS: The results of this large retrospective study indicate that increased GGT activities are independently associated with a more atherogenic lipid profile in general population.
BACKGROUND: Population-based epidemiological studies have shown a convincing association between increased gamma-glutamyltransferase (GGT) activity and components of the metabolic syndrome, type 2 diabetes, hypertension, ischaemic stroke and myocardial infarction. However, little information is available on the interaction between GGT activity and traditional or emerging markers of cardiovascular risk. METHODS: We performed a retrospective analysis to retrieve results of serum GGT, fasting plasma glucose (FPG), creatinine, LDL-cholesterol, HDL-cholesterol, triglycerides and lipoprotein(a) tests performed on outpatients referred by the general practitioners to our laboratory for routine blood testing during the last 5 years. RESULTS: The concentrations of most lipid parameters varied with increasing GGT activities. There were graded, positive, associations of GGT concentrations with LDL-cholesterol, triglycerides, atherogenic index of plasma (AIP) and the total to HDL-cholesterol ratio, whereas a negative association was observed with HDL-cholesterol. Lipoprotein(a) concentrations increased in parallel with GGT activity, though such trend did not reach statistical significance. The frequencies of subjects with undesirable values according to the NCEP-ATP III and AHA/ACC thresholds increased across the spectrum of GGT thresholds for all lipids parameters but lipoprotein(a). These associations remained statistically significant even after adjustment for gender, age, FPG and creatinine concentrations. In multiple linear regression analyses GGT activity predicted plasma concentrations of LDL-cholesterol, triglycerides, HDL-cholesterol (negatively), AIP and the total to HDL-cholesterol ratio independently of age, gender, impaired fasting glucose/diabetes and creatinine levels. CONCLUSIONS: The results of this large retrospective study indicate that increased GGT activities are independently associated with a more atherogenic lipid profile in general population.
Authors: Chad L Cox; Kimber L Stanhope; Jean Marc Schwarz; James L Graham; Bonnie Hatcher; Steven C Griffen; Andrew A Bremer; Lars Berglund; John P McGahan; Nancy L Keim; Peter J Havel Journal: Nutr Metab (Lond) Date: 2012-07-24 Impact factor: 4.169